Down 36%, Is Moderna a Buy on the Dip?
In many ways, the pandemic is becoming a faded memory. With that, a major pandemic star -- biotech Moderna (NASDAQ: MRNA) -- also seems to be disappearing from the world's attention. The company's stock is down a headache-inducing 36% year to date, compared to the S&P 500 index's mere 9% slide.This doesn't mean Moderna is inactive; in fact, it's quite the opposite. Let's see if that, combined with its considerable price weakness, makes it something of a stealth buy today.Moderna shot to prominence near the end of 2021, when its Spikevax coronavirus vaccine received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA). Continue reading
In many ways, the pandemic is becoming a faded memory. With that, a major pandemic star -- biotech Moderna (NASDAQ: MRNA) -- also seems to be disappearing from the world's attention. The company's stock is down a headache-inducing 36% year to date, compared to the S&P 500 index's mere 9% slide.
This doesn't mean Moderna is inactive; in fact, it's quite the opposite. Let's see if that, combined with its considerable price weakness, makes it something of a stealth buy today.
Moderna shot to prominence near the end of 2021, when its Spikevax coronavirus vaccine received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA).
